Freya Biosciences ApS
Quick facts
Marketed products
Phase 2 pipeline
- Chlorhexidine 0.5%
- FB 301 · Diabetes
FB 301 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Freya Biosciences ApS
What are Freya Biosciences ApS's marketed drugs?
Top marketed products include metronidazole 500 mg.
Related
- metronidazole 500 mg
- Sector hub: All tracked pharma companies